Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin - Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation

Next Previous
Drug Profile

Canagliflozin - Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine; Mundipharma Medical Company; Tai Tien Pharmaceuticals
  • Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Type 2 diabetes mellitus
  • Phase III Heart failure
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 24 Jul 2025 Preregistration for Type 2 diabetes mellitus (In adolescents, In children, Adjunctive treatment, In adults) in European Union (PO)
  • 24 Jul 2025 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommends extension of indication for Canagliflozin to include the treatment of Type II diabetes mellitus
  • 29 Apr 2025 Launched for Type 2 diabetes mellitus in Thailand (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top